Australia markets closed

Lumos Pharma, Inc. (LUMO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.5400-0.0600 (-1.67%)
At close: 04:00PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
1,486
2,051
1,523
230
168
-
Operating expenses
Research development
23,580
22,096
17,857
16,246
9,206
-
Selling general and administrative
15,527
16,569
15,706
15,331
17,265
-
Total operating expenses
39,107
38,665
33,563
31,577
26,471
-
Operating income or loss
-37,621
-36,614
-32,040
-31,347
-26,303
-
Interest expense
98
-
-
-
-
50
Total other income/expenses net
905
683
91
269
6,467
-
Income before tax
-35,749
-34,063
-31,075
-31,066
-19,636
-
Income tax expense
0
-29
-13
-636
-13,973
-
Income from continuing operations
-35,749
-34,034
-31,062
-30,430
-5,663
-
Net income
-35,749
-34,034
-31,062
-30,430
-5,663
-
Net income available to common shareholders
-35,749
-34,034
-31,062
-30,430
-6,314
-
Basic EPS
-3.99
-4.18
-3.71
-3.65
-0.93
-
Diluted EPS
-3.99
-4.18
-3.71
-3.65
-0.93
-
Basic average shares
8,217
8,145
8,374
8,335
6,778
-
Diluted average shares
8,217
8,145
8,374
8,335
6,778
-